MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

TAS-115

CAS No. : 1190836-34-0

MCE 站：TAS-115

产品活性：TAS-115 是一种有效的 VEGFR 和 c-Met/HGFR 抑制剂，能够抑制 rVEGFR2 和 rMET 的活性，IC₅₀ 值分别为 30 和 32 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：VEGFR  |  c-Met/HGFR

In Vitro: TAS-115 is ATP antagonism with inhibition constant (K_i) values against rVEGFR2 and rMET of 12 and 39 nM, respectively. AS-115 inhibits the kinase activity of both VEGFR2 and MET and their signal-dependent cell growth as strongly as other known VEGFR or MET inhibitors. TAS-115 induces less damage in various normal cells than do other VEGFR inhibitors. TAS-115 does not affect the growth of PC-9 or HCC827 cells at concentrations less than 10 μM; however, the combined use of TAS-115 with erlotinib reverses HGF-induced resistance in the cell lines in a concentration-dependent manner. TAS-115 inhibits VEGF production by cancer cells and endothelial proliferation.

In Vivo: TAS-115 (50 mg/kg/d) completely prevents tumor growth during the treatment period. TAS-115 (200 mg/kg/d) induces a 48% regression from the initial tumor volume in MET-amplified human cancer transplanted models. The estimated 50% effective dose (ED₅₀) of TAS-115 in this model is 8 mg/kg/d. TAS-115 significantly prolongs survival of these mice when administered at doses of 50 or 200 mg/kg/d. TAS-115 inhibits angiogenesis in PC-9/HGF tumors in vivo. Moreover, the doublet erlotinib and TAS-115 successfully inhibit PC-9/HGF tumor growth and delay tumor regrowth associated with sustained tumor vasculature inhibition even after cessation of the treatment.

相关产品：Bevacizumab  |  Sunitinib  |  Semaxinib  |  SU 5402  |  PD173074  |  5Z-7-Oxozeaenol  |  Cediranib  |  SAR131675  |  Gandotinib  |  GW806742X  |  Tanshinone IIA  |  PF-03814735  |  PHA-665752  |  2-Phospho-L-ascorbic acid trisodium  |  Vatalanib dihydrochloride  |  CP-547632  |  SU11274  |  AST 487  |  SRI 31215 TFA  |  Tyrphostin A9  |  Ki20227  |  Motesanib  |  SU14813  |  Ramucirumab  |  SU1498  |  MAZ51  |  PP121  |  Ki8751

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。